Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 32 Breast Neoplasms 18 Neoplasms 9 Triple Negative Breast Neoplasms 8 Neoplasm Metastasis 7 Sarcoma 6 Prostatic Neoplasms 6 Fanconi Anemia, Complementation Group D1 6 Pancreatic Neoplasms 5 Endometrial Neoplasms 5 Stomach Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Small Cell Lung Carcinoma 4 Recurrence 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Fallopian Tube Neoplasms 4 Colorectal Neoplasms 4 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Mesothelioma 2 Head and Neck Neoplasms 2 Glioma 2 Glioblastoma 2 Central Nervous System Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma 2 Advanced Solid Tumours 2 Advanced Solid Tumors 2 Wilms Tumor 1

Interventions

Prednisone 5 enzalutamide 4 cabazitaxel 4 Docetaxel 3 XRP6258 2 Abiraterone Acetate 2 sipuleucel-T 1 rucaparib 1 olaparib 1 apalutamide 1 Zuclomiphene 1 Standard of Care 1 Prednisolone 1 Lenograstim 1 LY3023414 1 Injections 1 Hematologic Tests 1 Granulocyte Colony-Stimulating Factor 1 Abituzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Prostate Cancer Metastatic × olaparib × Clear all

NCT03434158 2022-11-03

IMANOL

Spanish Oncology Genito-Urinary Group

Phase 2 Completed

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡